OmniAb (OABI) Q3 2025: Program Count Hits 399, OmniUltra Launch Expands Peptide Market Access
OmniAb’s Q3 showcased record partner and program growth, even as revenue softness reflected milestone timing and service mix shifts. The company’s strategic launch of OmniUltra, a transgenic chicken platform for ultra-long CDRH3 antibody and peptide discovery, signals a push into new therapeutic modalities and near-term service revenue. With a strengthened balance sheet and cost discipline, OmniAb is positioned to capitalize on partner expansion and innovation-led business model leverage into 2026.
Summary
- OmniUltra Platform Debut: Launching in December, OmniUltra opens new peptide and antibody discovery markets.
- Record Partner and Program Base: Active partners surpassed 100, with 399 programs now leveraging OmniAb technology.
- Milestone Timing Drives Revenue Lull: Soft Q3 revenue reflects milestone pushouts, but underlying program momentum remains robust.
Performance Analysis
OmniAb’s Q3 2025 financials reflected a transitional period as service revenue and milestone receipts lagged prior-year levels, resulting in a revenue decline to $2.2 million from $4.2 million a year ago. The primary driver was a reduction in milestone achievements and lower service revenue, as several small molecule ion channel programs concluded earlier in the year. Offsetting this, the company began to recognize initial revenue from its new Exploration platform, which is expected to become a recurring source via consumables and subscriptions as the installed base grows.
Operating expenses fell sharply to $20.4 million, a $3.5 million reduction year-over-year, driven by headcount realignment, lower stock-based compensation, and decreased external R&D. A non-recurring $0.8 million charge related to headcount reduction was absorbed in the quarter. The net loss was essentially flat versus Q3 2024, despite the revenue shortfall, reflecting improved cost leverage. The balance sheet was reinforced by a $30 million private placement, leaving $59.5 million in cash at quarter-end and providing runway through expected milestone timing shifts into 2026.
- Milestone Revenue Deferral: Several anticipated milestones were pushed to 2026 due to partner timing, not program attrition.
- Cost Discipline: R&D and G&A expense cuts supported margin stability despite lower revenue.
- Exploration Platform Contribution: Early sales of consumables and positive partner feedback lay groundwork for future recurring revenue streams.
Underlying operating metrics tell a different story than the top line: active partner count reached a record 104, with 18 net new programs added in Q3 (36 year-to-date), and 61 post-discovery programs now representing $1.3 billion in potential milestones. The company’s program base and downstream royalty potential continue to build, even as near-term financials remain milestone-dependent.
Executive Commentary
"We continued to have nice deal flow throughout the third quarter, and the number of new program additions this year is far outpacing last year. Our program ads as of the end of Q3 already equaled the program ads we had in all of 2024. We've also grown and diversified our base of active partners, reaching a record high level, now exceeding 100."
Matt Foer, President and Chief Executive Officer
"We now expect that 2025 revenue will be between 18 and 22 million, and operating expense will be between 82 and 86 million dollars. We continue to expect that our cash use in 2025 will be lower than the cash used in 2024, excluding financings of both years, and we expect our year-end cash balance to be between $52 and $56 million."
Kurt Gustafson, Chief Financial Officer
Strategic Positioning
1. Expanding Technology Stack with OmniUltra
OmniUltra, transgenic chicken platform for ultra-long CDRH3s, launches in December and positions OmniAb to capture value in both antibody and peptide therapeutic discovery. By engineering chickens to produce cow-like antibodies with unique structural features, OmniUltra enables access to previously unreachable biological targets and opens new partnership opportunities, especially in the high-growth peptide space fueled by GLP-1 drug momentum.
2. Business Model Diversification and Recurring Revenue
With the Exploration Partner Access Program, high-throughput B-cell screening platform, OmniAb is building a dual-revenue model combining traditional technology licensing (milestones, royalties) with recurring revenue from consumables, software, and service contracts. Early feedback from partners highlights efficiency gains, and the company expects Exploration to be accretive to both earnings and cash flow, deepening partner engagement and stickiness.
3. Partner and Program Growth as Leading Indicators
Despite milestone-related revenue volatility, OmniAb’s partner base and active program count set new records. The company now supports 399 programs across 104 partners (over half US-based, with rising international presence). The pipeline includes 32 clinical-stage programs, with two in registration and five projected to enter clinical development by year-end. These metrics underpin future milestone and royalty potential, even as short-term revenue fluctuates.
4. R&D Efficiency and Financial Flexibility
Operating cost reductions and a $30 million capital raise have extended OmniAb’s cash runway, providing the flexibility to weather milestone timing shifts and invest in core technology launches. About 40% of operating expense remains non-cash, providing further buffer, and management expects cash use to decline year-over-year, excluding financing activity.
Key Considerations
OmniAb’s Q3 was marked by milestone revenue deferral offset by robust underlying business development and platform expansion. The company’s ability to add programs and partners at a record pace, while launching new discovery technologies, signals a business model transition toward greater scale and recurring revenue.
Key Considerations:
- OmniUltra Launch Timing: The December debut targets both existing antibody partners and new peptide-focused entrants, potentially accelerating near-term service revenue and long-term royalty streams.
- Exploration Platform Uptake: Strong demand for demos and positive partner feedback suggest a growing installed base, with recurring consumable and software revenue to follow.
- Milestone and Royalty Pipeline: With two programs at registration (notably SAL003, anti-PCSK9, in China) and several high-profile phase 2/3 assets, downstream economics could ramp materially from 2026 onward.
- Cost Flexibility: Operating expense reductions and capital raise provide a buffer against milestone timing risk and support ongoing innovation investment.
Risks
Milestone and royalty revenue remain highly event-driven and dependent on partner clinical progress, exposing OmniAb to timing risk outside its direct control. Delays in partner R&D or regulatory approvals can defer revenue recognition, while competitive pressures in antibody and peptide discovery may challenge technology differentiation. Continued cash burn, even at reduced levels, will require sustained program momentum and eventual commercial-stage royalty conversion to support long-term self-funding.
Forward Outlook
For Q4 2025, OmniAb guided to:
- Revenue between $18 million and $22 million for the full year
- Operating expense between $82 million and $86 million
For full-year 2025, management expects:
- Year-end cash balance of $52 million to $56 million
Management highlighted several factors that will shape near-term results:
- Milestone receipts now expected in 2026, with program additions and partner engagement remaining strong
- OmniUltra and Exploration platform launches to expand service and recurring revenue channels
Takeaways
OmniAb’s underlying business momentum—reflected in partner and program growth—contrasts with near-term revenue softness driven by milestone timing. The company’s innovation pipeline, led by OmniUltra, and the expansion of recurring revenue platforms position it to benefit from sector tailwinds in antibody and peptide therapeutics.
- Platform Expansion Drives Opportunity: OmniUltra’s launch broadens addressable markets and supports service revenue growth, while Exploration’s uptake provides a recurring revenue lever.
- Financial Flexibility Mitigates Timing Risk: Cost controls and the recent capital raise extend runway and support continued innovation investment.
- Milestone and Royalty Ramp Key for 2026: Investors should focus on clinical progress of registration and late-stage programs, as these will drive the next phase of financial inflection.
Conclusion
OmniAb’s Q3 2025 results illustrate a business in transition, with record program and partner expansion offsetting milestone-driven revenue volatility. The company’s strategic launch of OmniUltra and focus on recurring revenue platforms set the stage for long-term growth, but sustained execution on partner pipeline conversion and milestone realization will be critical for value creation in 2026 and beyond.
Industry Read-Through
OmniAb’s results highlight a sector-wide shift toward platform diversification and recurring revenue models in antibody and peptide discovery. The launch of OmniUltra reflects increased industry focus on novel modalities and biologically engineered hosts to address previously inaccessible targets, paralleling trends in GLP-1 and peptide therapeutics. The milestone timing volatility seen here is likely mirrored across platform biotech, where partner-driven revenue remains event-based. For peers, the ability to convert innovation into downstream economics and build recurring revenue channels will be key to sustainable growth as the discovery landscape becomes more competitive and capital intensive.